In under six months, Eli Lilly has committed more than $20 billion to ten acquisitions, seven of them in the last three months alone. It has bought a sleep-disorder biotech, three vaccine makers, two in vivo CAR-T developers, an antibody-drug-conjugate specialist and a blood-cancer pipeline. It has not bought a single tablet.
The figures below are drawn from Eli Lilly’s own investor announcements and SEC filings, and from reporting by Bloomberg, CNBC, C&EN, BioPharma Dive, BioSpace and the Motley Fool, every deal traceable to its own primary-source disclosure.
By Ibumix · 15-minute read
1. The headline that ought to be a headline
In the first quarter of 2026, Eli Lilly reported revenue of $19.8 billion. Mounjaro alone contributed $8.66 billion, up 125% year on year. Zepbound added a further $4.16 billion. Between them, two GLP-1 medicines now account for close to two-thirds of the company’s quarterly revenue, the kind of concentration most chief executives would spend a career defending.
Eli Lilly’s chief executive, David Ricks, is spending against it. Since March 2026, Lilly has committed more than $20 billion to ten acquisitions, seven of them announced in the last three months alone, a faster pace of dealmaking than the company managed in the whole of the previous year.
The company generating the most predictable windfall in pharmaceutical history is the one spending it fastest on becoming less predictable.
2. Ten deals, six months — the numbers
The acquisitions span cell therapy, oncology, sleep medicine, vaccines and gene-delivery technology. Read as a single portfolio, they are not a scatter of opportunistic bolt-ons. They are a coherent bet on which technologies sit outside the GLP-1 franchise but close enough to Lilly’s existing manufacturing, regulatory and commercial muscle to be worth owning outright.
| Acquisition | Disclosed value | What it buys | Announced |
|---|---|---|---|
| Orna Therapeutics | Up to $2.4bn | In vivo CAR-T cell therapy | February 2026 |
| Centessa Pharmaceuticals | Up to $7.8bn | Sleep-wake disorders (narcolepsy, excessive daytime sleepiness) | March 2026 |
| Kelonia Therapeutics | Up to $7bn | In vivo CAR-T cell therapy | April 2026 |
| CrossBridge Bio | Up to $300m | Dual-payload antibody-drug conjugates (oncology) | April 2026 |
| Ajax Therapeutics | Up to $2.3bn | Blood-cancer pipeline | 2026 |
| Ventyx Biosciences | $1.2bn | Oral small-molecule therapies for inflammatory disease | 2026 |
| Engage Biologics | $203m | Non-viral DNA delivery | 2026 |
| Three vaccine developers | Not fully disclosed | Vaccine manufacturing and pipeline, a category new to Lilly | May 2026 |
Disclosed values are milestone-inclusive maxima as announced by each company; not all represent guaranteed cash outlay. The three vaccine acquisitions were reported by C&EN in May 2026 without individual deal values disclosed at the time of writing.
3. The dealmaker’s own words
The scale of the spending is deliberate, not defensive. According to CNBC’s reporting, Ricks approached Jacob Van Naarden, the executive running Lilly’s oncology business, last autumn about taking on business development as an additional role, specifically to sharpen the company’s dealmaking and start “widening its aperture beyond the early bets where Lilly liked to focus.” Van Naarden has since said the deals are all part of a plan to grow beyond the GLP-1 drugs for obesity and diabetes the company is best known for.
Lilly has also been explicit that the GLP-1 windfall itself is funding the diversification: CNBC reported in June 2026 that the company intends to use GLP-1 cash flow directly to fund further M&A. The logic is straightforward and, by pharma standards, unusually candid — the current growth engine is being used, in real time, to build the next one, rather than waiting for growth to slow first.
The same instinct shows up outside dealmaking. Lilly has partnered with Nvidia to build an AI drug-discovery lab, and Ricks has pointed to neuroscience as a long-term priority in its own right: “The brain is maybe the final frontier of biology and medicine, but Lilly’s at the front edge of that.”
4. What the deals have in common — and the one that doesn’t
Grouped by modality rather than headline, a pattern emerges. Orna and Kelonia are in vivo CAR-T developers, cell therapy engineered inside the patient’s body rather than manufactured outside it, a delivery paradigm with almost nothing in common with a tablet press. CrossBridge Bio’s antibody-drug conjugates are infused or injected biologics with a targeted payload. The three vaccine acquisitions place Lilly, for the first time at this scale, in a commercial category it has not historically competed in. Centessa’s sleep-wake portfolio and Ajax’s blood-cancer pipeline extend Lilly into therapeutic areas it does not currently lead.
One deal does not fit that story, and this piece is weaker for pretending otherwise. Ventyx Biosciences, at $1.2 billion, is an oral small-molecule portfolio for inflammatory disease, Lilly’s most traditional format, in a new indication rather than a new modality. It is roughly 5% of the disclosed deal value reviewed here. Ventyx is the exception; it is not large enough to change the shape of the pattern around it.
Strip Ventyx out and the remaining $19bn-plus is aimed almost entirely at technologies that are not swallowed as a compressed solid: cell therapy administered by infusion, antibody-drug conjugates given intravenously, vaccines given by injection. Lilly’s own current fortune, Mounjaro and Zepbound, is injectable too. A company built on an injection is spending that fortune on more things that are not pills.
5. The precedent: why Camurus, why lipid liquid-crystal
The 2026 acquisitions were not Lilly’s first move into this territory. A year earlier, in June 2025, Lilly signed a licensing deal, not an acquisition, with Camurus, a Swedish drug-delivery specialist, for exactly this asset class: lipid liquid-crystal depot technology, branded FluidCrystal.
The terms: exclusive worldwide rights to use FluidCrystal for up to four of Lilly’s own incretin compounds — a dual GIP/GLP-1 agonist, a triple GIP/glucagon/GLP-1 agonist, and an option to include an amylin agonist — for up to $870 million: $290 million in upfront and development/regulatory milestones, $580 million in sales milestones, plus tiered mid-single-digit royalties on net sales.
FluidCrystal itself is a simple idea, precisely engineered. It is a lipid solution — glycerol dioleate and soy phosphatidylcholine, with a trace of NMP solvent — thin enough to draw into an ordinary syringe or pen. On contact with body fluid after injection, it spontaneously reorganises into a liquid-crystalline gel, which then degrades gradually over days to months, releasing the drug as it goes. No implant, no pump, no complex device — a single subcutaneous injection standing in for weeks or months of dosing. It works across small molecules, peptides and proteins, which is precisely why Lilly’s own incretin peptides are a fit.
The commercial logic is direct. Mounjaro and Zepbound are weekly injections. A version of the same molecule class that lasts a month rather than a week is a genuine adherence lever and a competitive one, the reason a company already generating close to $9 billion a quarter from Mounjaro alone would pay to explore turning weekly dosing into a monthly product instead.
Lilly is not the platform’s first validation, and the wider picture is worth setting out honestly rather than cherry-picked. Camurus’ longest-running commercial relationship is with Braeburn Pharmaceuticals: an exclusive licence signed in November 2014 for FluidCrystal buprenorphine (CAM2038), worth up to $151 million in total — $20 million upfront, $35 million and $21 million in development milestones for opioid dependence and pain respectively, up to $75 million in sales milestones, and mid-teen royalties. The product is marketed as Brixadi in North America and Buvidal in the rest of the world. The companies expanded the collaboration in October 2016 to add a buprenorphine-granisetron combination product for postoperative pain and nausea, with further development milestones attached that neither company has disclosed. The original 2014 relationship also survived a 2020 arbitration dispute, resolved in the licence’s favour, a useful reminder that even a validated platform’s licensing relationships are not always friction-free.
More recently, in December 2025, Camurus licensed the platform inbound as well as out: an agreement with Gubra combines Gubra’s parathyroid-hormone analogues with FluidCrystal to develop a long-acting hypoparathyroidism treatment, with Camurus handling development and commercialisation and Gubra taking tiered royalties in place of a disclosed upfront fee. And Camurus runs its own pipeline on the same base technology — Buvidal; Oczyesa, a long-acting octreotide depot; and CAM2056, an investigational monthly semaglutide depot that, in Phase 1b data reported in November 2025, produced a 9.3% weight reduction against 5.2% for weekly semaglutide in the same trial, a treatment difference large enough, at p=0.008, to be more than noise.
Four deals, one platform, one recurring reason: a molecule that needs weekly or daily dosing becomes a molecule that needs one injection a month, without a new device, just a different lipid.
That is the same argument this piece has been making about Lilly’s 2026 acquisitions, running one layer deeper. The company was not guessing when it wrote the cheque for cell therapy, ADCs and vaccines. It had already paid, a year earlier and at smaller scale, to test the same underlying belief — that the format a molecule is delivered in is now as commercially valuable as the molecule itself — against its own best-selling drug class.
6. Two incumbents, two playbooks
Ibumix examined Pfizer’s equivalent transition in a companion piece, The End of the Tablet Era. The contrast between the two incumbents is instructive precisely because both are moving in the same direction by opposite routes.
Pfizer’s defining move was a single, enormous bet: the $43 billion acquisition of Seagen in 2023, bought specifically for its antibody-drug-conjugate portfolio. Having placed that bet, Pfizer’s 2026 posture is now one of ruthless narrowing, trade press has described the company abandoning “science projects” that fail an internal return-on-investment bar, concentrating around fewer, higher-conviction assets.
Lilly’s posture is the mirror image: not one large bet but ten medium ones, spread across cell therapy, oncology, sleep medicine and vaccines, placed while the core GLP-1 franchise is still compounding rather than after it has slowed. Pfizer bet big once, then cut everything else back. Lilly is placing many bets simultaneously, insured by a windfall it has not yet had to defend.
Concentration versus diversification is not a disagreement about whether the tablet era is ending. It is a disagreement about how much to risk finding out what replaces it.
7. What even Lilly’s own pipeline still needs
The diversification story has a limit worth naming honestly. Despite committing billions to injectable cell therapy, infused biologics and vaccines, Lilly is simultaneously developing more than half a dozen new GLP-1 medicines, including orforglipron, an oral small-molecule GLP-1 mimic engineered specifically to reach patients who will not or cannot inject.
That single fact is the tell. Even the company placing its most aggressive bets on cell therapy and injectable biologics knows that chronic-disease medicine, at global population scale, ultimately needs an oral answer. A daily injection does not scale to hundreds of millions of patients the way a daily tablet does. Orforglipron’s route to “oral” is to redesign the molecule itself until it no longer needs the permeation problem solved for it, one legitimate answer to the same underlying question Ibumix’s own work addresses from the formulation side: how does a molecule that was never built for the gut actually get through it.
Ibumix’s earlier piece, The End of the Tablet Era, and this one are, underneath the different companies, the same question asked twice: not whether the tablet disappears, but which molecules still need one, and what has to change about the format itself to keep serving them.
8. Ibumix made this case before the spending started
This piece has read Lilly’s 2026 acquisitions as evidence of a structural shift away from the tablet. That reading did not start with Lilly’s spending. It is a position Ibumix set out in writing, in public, across three separate pieces published between March and May 2026, before Lilly’s acquisition pace accelerated through the second quarter. None of the three named Lilly. They did not need to.
In April 2026, Ibumix argued in AI Designed the Molecule. It Still Failed the Patient. that AI-driven discovery and drug delivery are not competing investments but complementary ones, and that the formulation layer — not the discovery layer — is the underdeveloped bottleneck standing between AI’s gains and clinical success: “the future of medicine will be determined not only by what can be designed, but by what can be absorbed.” Lilly’s own 2026 behaviour tracks that argument closely: an AI drug-discovery partnership with Nvidia, running in parallel with, not instead of, a run of acquisitions aimed squarely at the delivery and format side of the business.
The companion piece above, The End of the Tablet Era, made the demographic case in May 2026: roughly one adult in six has difficulty swallowing a tablet, rising toward 40% in patients over seventy, and the fastest-growing patient populations in pharma — ageing patients in developed markets, paediatric populations in developing ones — are the ones a compressed solid serves worst. Vaccines, cell therapy and injectable biologics do not carry that failure mode. A tablet does.
And in March 2026, before any of this year’s acquisitions were announced, Ibumix argued in Standard Dosing Is Fundamentally Broken that the tablet’s fixed geometry is itself the constraint: a discrete solid object cannot offer the continuous, patient-specific dosing that liquid-based systems can. Lilly is not building liquid delivery platforms. But cell therapy, ADCs and vaccines — and the Camurus deal a year before them — are each, in their own way, a vote for formats with more degrees of freedom than a fixed-dose tablet.
Ibumix did not read this pattern into Lilly’s spending after the fact. It published the pattern first.
None of this claims Ibumix foresaw Eli Lilly specifically, and it would be a smaller, less interesting claim if it did. What it claims is narrower and more useful: the industry-level argument Ibumix has been making in public since March, about AI, demographics and dosing geometry converging on the same conclusion, is the argument Lilly’s chequebook is now the largest single piece of evidence for.
9. The orientation that follows
A pharmaceutical company’s acquisition ledger is a more honest forecast than its investor presentation. A slide can claim any future a company likes; a wire transfer has to be defended to a board. Read that way, Lilly’s ledger over the last six months says something specific: the company with the single most valuable injectable franchise in the industry does not believe the next decade of medicine looks like the last one, and it is prepared to spend more than $20 billion finding out what does.
There is also a less flattering read of the same evidence, and it deserves stating rather than dismissing. Diversification of this kind can be as much hedge as conviction: GLP-1 pricing pressure from PBMs, and the prospect of Medicare price negotiation reaching Mounjaro and Zepbound under the Inflation Reduction Act, put a ceiling on how long the current growth rate can be extrapolated, and a company facing that ceiling has every reason to build alternative growth lines while the cash is still there to pay for them. Competitive pressure from Novo Nordisk’s own pipeline cuts the same way. None of that requires Lilly to believe anything in particular about the future of the tablet, only that its own best-selling franchise will not stay this dominant indefinitely, which is a narrower and more defensive claim than the one this piece has been making.
Offence or defence, the direction of travel is the same, and it is the direction Ibumix named before this year’s spending began. Ten deals. Not one of them a tablet. That is not an accident of timing. It is a capital allocator’s answer to the same question the rest of the industry is still debating in public, whether the motive is offence, defence, or both at once.
The question is no longer whether the tablet era ends. Lilly’s chequebook has already answered it.
Ibumix is developing a series of new liquid drug delivery platforms designed to solve exactly the class of problem this piece describes — molecules that do not fit the tablet by default, and need a format built around absorption and consistency from the first sketch.
Update, 17 July 2026
A day after this piece published, Lilly announced an eleventh deal: AtaiBeckley, acquired for up to $3.8bn (reported as $2.8bn upfront in cash, plus up to $1bn in development and regulatory milestones), moving into psychedelic-based treatment for treatment-resistant depression. A new therapeutic area again, not an extension of cell therapy, oncology or vaccines — and, once more, not a tablet. The count and totals above reflect Lilly’s acquisitions through 15 July 2026; the eleventh deal only strengthens the pattern this piece describes.
Sources: Bloomberg, STAT News, CNBC.
Sources
- Eli Lilly and Company — Q1 2026 Sales and Earnings (SEC Form 8-K). sec.gov
- Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders — investor.lilly.com. investor.lilly.com
- Lilly to buy narcolepsy drug developer for $6.3-7.8 billion — C&EN. cen.acs.org
- CrossBridge Bio Enters an Agreement to be Acquired by Eli Lilly — BusinessWire. businesswire.com
- Lilly boosts ADC portfolio with CrossBridge Bio deal — BioPharma Dive. biopharmadive.com
- Lilly’s M&A team strikes again with $2.3bn Ajax takeover — pharmaphorum. pharmaphorum.com
- Eli Lilly outlays $2.3bn to acquire blood cancer specialist Ajax Therapeutics — Pharmaceutical Technology. pharmaceutical-technology.com
- Lilly will buy 3 vaccine firms in “power move” — C&EN. cen.acs.org
- Lilly’s 7 Acquisitions in 3 Months — The Motley Fool. fool.com
- Eli Lilly Commits Over $20 Billion to Acquisitions in 2026 Expansion Drive — Bloomberg. bloomberg.com
- Eli Lilly to use GLP-1 windfall to fund M&A and diversify pipeline — CNBC. cnbc.com
- Lilly can’t stop the dealing, with nearly $21B spent on M&A this year — BioSpace. biospace.com
- AI and GLP-1 drugs: Eli Lilly & Co.’s CEO talks of focus beyond 150 years — WRTV. wrtv.com
- Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal incretins — Camurus, June 2025. camurus.com
- Eli Lilly enlists Camurus to help unlock long-acting obesity market in deal worth up to $870M — Fierce Biotech. fiercebiotech.com
- FluidCrystal injection depot — technology overview, Camurus. camurus.com
- Camurus and Braeburn Pharmaceuticals sign exclusive license — Camurus, November 2014. camurus.com
- Camurus, Braeburn Pharmaceutical Ink Licensing Deal Worth Up To $151 Million — BioSpace. biospace.com
- Braeburn Pharmaceuticals and Camurus Expand Collaboration and License Agreement — Camurus, October 2016. camurus.com
- Camurus announces outcome of the arbitration process with Braeburn — Camurus, 2020. camurus.com
- Gubra and Camurus enter into a collaboration and license agreement — Camurus, December 2025. camurus.com
- Camurus reports positive topline results for CAM2056 — Camurus, November 2025. camurus.com
- Ibumix — AI Designed the Molecule. It Still Failed the Patient. (6 April 2026). ibumix.com
- Ibumix — The End of the Tablet Era (30 May 2026). ibumix.com
- Ibumix — Standard Dosing Is Fundamentally Broken (30 March 2026). ibumix.com